Experimental CMT drug passes first safety check in small study
NCT ID NCT06328712
First seen Jan 10, 2026 · Last updated May 20, 2026 · Updated 20 times
Summary
This early-stage trial tested the safety of a new drug called EN001 in 6 adults with Charcot-Marie-Tooth disease type 1A (CMT1A), a nerve disorder that causes muscle weakness. Researchers gave increasing doses to see if the drug caused any serious side effects. The study is complete, but results are not yet available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHARCOT-MARIE-TOOTH DISEASE, TYPE 1A are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Samsung Medical Center
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.